Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza Vaccination
- First Posted Date
- 2006-06-13
- Last Posted Date
- 2009-12-17
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 156
- Registration Number
- NCT00336453
- Locations
- 🇺🇸
Kentucky pediatric /Adult Research, Bardstown, Kentucky, United States
🇺🇸Primary Physicians Research, Pittsburg, Pennsylvania, United States
🇺🇸Saint Louis University, Saint Louis, Missouri, United States
Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza Vaccine, recombinant Hemagglutinin
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 459
- Registration Number
- NCT00328107
- Locations
- 🇺🇸
Rochester Medical Center, Rochester, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸University of Virginia Health System, Charlottesville, Virginia, United States
© Copyright 2025. All Rights Reserved by MedPath